Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 3418
Gene Symbol: IDH2
IDH2
0.100 Biomarker disease BEFREE <b>Abbreviations</b>: CGGA: Chinese Glioma Genome Atlas; TCGA: The Cancer Genome Atlas; TAMs: Tumor associated macrophages; IDH: isocitrate dehydrogenase; GBM: glioblastoma. 31143523 2019
Entrez Id: 3418
Gene Symbol: IDH2
IDH2
0.100 GeneticVariation disease BEFREE Doomed from the TERT? A Two-Stage Model of Tumorigenesis in IDH-Wild-Type Glioblastoma. 30991024 2019
Entrez Id: 3418
Gene Symbol: IDH2
IDH2
0.100 Biomarker disease BEFREE GTR and MGMT promoter methylation are independent prognosticators for improved overall and progression-free survival in a homogeneous cohort of newly diagnosed patients with IDH wild-type glioblastoma. 29617848 2019
Entrez Id: 3418
Gene Symbol: IDH2
IDH2
0.100 Biomarker disease BEFREE T1+Gad performed best for IDH typing of glioblastoma (sensitivity 91.9%, specificity 100%, AUC 0.945) and ADC for non-Gadolinium-enhancing gliomas (sensitivity 85.7%, specificity 78.4%, AUC 0.877). 30927935 2019
Entrez Id: 3418
Gene Symbol: IDH2
IDH2
0.100 Biomarker disease BEFREE From Jan 2009 to Dec 2016, 161 patients with newly diagnosed IDH-wild type GB were treated with surgery and adjuvant concurrent chemoradiotherapy with the Stupp's regimen, and then genomic research proceeded with their surgical specimens. 30773189 2019
Entrez Id: 3418
Gene Symbol: IDH2
IDH2
0.100 GeneticVariation disease BEFREE Recent DNA methylation analyses revealed a small group of IDH mutant diffuse gliomas exhibiting decreased DNA hypermethylation resulting in substantial unfavorable prognosis comparable to glioblastoma. 30937703 2019
Entrez Id: 3418
Gene Symbol: IDH2
IDH2
0.100 GeneticVariation disease BEFREE Patients with IDH wild type anaplastic astrocytoma and glioblastoma had a significantly shorter median PFS (19.3 months vs. NR, p = 0.001) and median OS (43.5 months vs NR, p = 0.007) than those with IDH mutated grade III anaplastic astrocytoma and oligodendroglioma. 31371189 2019
Entrez Id: 3418
Gene Symbol: IDH2
IDH2
0.100 Biomarker disease BEFREE In this study, we compared the two groups of survival outliers of glioblastoma with IDH wild-type, consisting of the glioblastoma patients who lived longer than 3 years (n = 17) and the patients who lived less than 1 year (n = 12) in terms of genome-wide DNA methylation profile. 31159876 2019
Entrez Id: 3418
Gene Symbol: IDH2
IDH2
0.100 Biomarker disease BEFREE The diagnosis was glioblastoma IDH-wild type, for which he underwent adjuvant therapy.Surgical anatomy and technical nuances of this approach are illustrated using a 3-dimensional video and anatomic dissections. 29878277 2018
Entrez Id: 3418
Gene Symbol: IDH2
IDH2
0.100 Biomarker disease BEFREE <b>Conclusion:</b> High radiation doses to ipsilateral NSC and contralateral SVZ could have a negative impact on overall survival in IDH-wild-type glioblastoma population. 30338243 2018
Entrez Id: 3418
Gene Symbol: IDH2
IDH2
0.100 Biomarker disease BEFREE GPR158 promotes glioma stem cell differentiation and induces apoptosis and is highest expressed in the cerebral cortex and in oligodendrogliomas, lower in IDH mutant astrocytomas and lowest in the most malignant form of glioma, IDH wild-type glioblastoma. 29720725 2018
Entrez Id: 3418
Gene Symbol: IDH2
IDH2
0.100 Biomarker disease BEFREE The majority of World Health Organization grade II and grade III gliomas harbor heterozygous mutations in the metabolic enzyme isocitrate dehydrogenase 1 (IDH1), and tumors with an IDH wild-type status show molecular features of a glioblastoma and simply may constitute a separate disease entity. 29548051 2018
Entrez Id: 3418
Gene Symbol: IDH2
IDH2
0.100 GeneticVariation disease BEFREE Characterization of diverse immune responses will facilitate patient stratification and improve personalized immunotherapy in the future.<b>Significance:</b> This study utilizes a computational approach to characterize the immune environments in glioblastoma and shows that glioblastoma immune microenvironments can be classified into three major subgroups, which are linked to typical glioblastoma alterations such as IDH mutation, NF1 inactivation, and CDK4-MARCH9 locus amplification.<b>Graphical Abstract:</b> http://cancerres.aacrjournals.org/content/canres/78/19/5574/F1.large.jpg <i></i>. 29921698 2018
Entrez Id: 3418
Gene Symbol: IDH2
IDH2
0.100 GeneticVariation disease BEFREE • Significant correlation exists between radiological parameters such as volumetric and ADC values and major genomic profiles such as IDH mutation and ATRX loss status • Radiological parameters such as the ADC value were feasible predictors of glioblastoma patients' prognosis • Imaging features can predict major genomic profiles of the tumours and the prognosis of glioblastoma patients. 29721688 2018
Entrez Id: 3418
Gene Symbol: IDH2
IDH2
0.100 GeneticVariation disease BEFREE We excluded glioblastoma-like tumors (7a10d subgroup) and derived a gene expression signature distinguishing histologically classified oligodendrogliomas with concurrent 1p/19q co-deletion and IDH mutation (1p/19q subgroup) from those with predominant IDH mutation alone (IDHme subgroup). 29631562 2018
Entrez Id: 3418
Gene Symbol: IDH2
IDH2
0.100 GeneticVariation disease BEFREE We analyzed The Cancer Genome Atlas dataset (TCGA) and identified a small group of IDH-mutant, WHO grade II-III astrocytomas (n = 14) with an unexpectedly poor prognosis characterized by a rapid progression to glioblastoma and death within 3 years of the initial diagnosis. 29741737 2018
Entrez Id: 3418
Gene Symbol: IDH2
IDH2
0.100 Biomarker disease BEFREE No survival difference was noted between patients with glioblastoma harboring the SNP and patients with IDH wild type glioblastoma. 29423539 2018
Entrez Id: 3418
Gene Symbol: IDH2
IDH2
0.100 Biomarker disease BEFREE Differential expression of circRNAs may be associated with IDH-wt glioblastoma development and progression, and these circRNAs can be identified as biomarkers for prognosis prediction and targets for treatment. 29920451 2018
Entrez Id: 3418
Gene Symbol: IDH2
IDH2
0.100 Biomarker disease BEFREE After chemoradiation with concomitant and adjuvant temozolomide, 21 IDH wild-type glioblastoma patients at first progression (age range, 33-75 years; MGMT promoter unmethylated, 81%) were treated with BEV/LOM. 29982845 2018
Entrez Id: 3418
Gene Symbol: IDH2
IDH2
0.100 PosttranslationalModification disease BEFREE Addition of 2-HG to glioblastoma cultures recapitulates the effects of the IDH mutation on intrinsic apoptosis, shuts down oxidative phosphorylation and reduces ATP levels in glioblastoma cells. 29057925 2017
Entrez Id: 3418
Gene Symbol: IDH2
IDH2
0.100 GeneticVariation disease BEFREE Rapid progression to glioblastoma in a subset of IDH-mutated astrocytomas: a genome-wide analysis. 28421459 2017
Entrez Id: 3418
Gene Symbol: IDH2
IDH2
0.100 Biomarker disease BEFREE The recent 2016 WHO classification for CNS tumors categorizes diffuse glioma into two major types that include IDH wild-type glioblastoma, which is the predominant type and IDH-mutant glioblastoma, which is less common and displays better prognosis. 28730141 2017
Entrez Id: 3418
Gene Symbol: IDH2
IDH2
0.100 AlteredExpression disease BEFREE In low-grade glioma (LGG) and glioblastoma cohorts of TCGA, significantly higher PD-L1 gene expression levels were evident in IDH-wt compared with IDH-mut samples (LGG: N = 516; P = 1.933e-11, GBM: N = 161; P < 0.009). 28531337 2017
Entrez Id: 3418
Gene Symbol: IDH2
IDH2
0.100 Biomarker disease BEFREE All patients were diagnosed with IDH-wild type glioblastoma according to pathological criteria. 29212499 2017
Entrez Id: 3418
Gene Symbol: IDH2
IDH2
0.100 Biomarker disease BEFREE H3-/IDH-wild type pediatric glioblastoma is comprised of molecularly and prognostically distinct subtypes with associated oncogenic drivers. 28401334 2017